Use VigiFlow to support your vaccine safety surveillance in a timely and efficient manner.
Monitoring adverse events following immunisation (AEFI) is an essential strategy for ensuring the safety of vaccines. In response to the COVID-19 pandemic, we’re increasing support for vaccine safety surveillance in UMC’s pharmacovigilance products.
VigiFlow is currently evolving to meet the needs of national vaccine safety surveillance. This allows for rapid identification of any safety concern regarding vaccines.
In collaboration with WHO and other stakeholders, we are expanding VigiFlow to support facilitated reporting and analysis of adverse events following immunisation (AEFI) for immunisation programmes (at district, provincial, and national levels). The AEFI expansion provides support for data capture (including the core variables for AEFI) and analysis facilitated by a customised line listing. VigiFlow also supports reporting statistics and controlled sharing of reports with the WHO Programme for International Drug Monitoring (PIDM).
We plan to release the new functionality mid-January 2021. Development will then continue to focus on supporting effective vaccine safety surveillance as a complement to the existing ICSR management support. We are also preparing for VigiLyze developments.
As an introduction, we have prepared a series of short videos showing how to enter and analyse the AEFI data in VigiFlow.
There is also a quick start guide, aimed at new VigiFlow users from immunization programmes to quickly get started in the system.
In addition, we are planning webinars in three languages, where we will focus on the new data entry form, WHODrug coding aspects of COVID-19 vaccines, and AEFI line listing. Register for the webinars here:
The webinars will be recorded and posted on this website.
Explore these improvements and possibilities in VigiFlow together with us. Please contact firstname.lastname@example.org for more information
This site will be continuously updated with new information as it becomes available.